Publications

Development of an end-to-end Quantitative Model-Informed Drug Development (MIDD) ECOSYSTEM

Using Read-Across to build Physiologically-Based Kinetic models: Part 2. Case studies for atenolol and flumioxazin

Using read-across to build physiologically-based kinetic models: Part 1. Development of a KNIME workflow to assist analogue selection for PBK modelling

Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment

Studying metabolism with multiorgan chips: new tools for diseasemodelling, pharmacokinetics and pharmacodynamics

Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans

Local depletion of large molecule drugs due to target binding in tissue interstitial space

Quantitative adverse outcome pathway (qAOP) models for toxicityprediction

Towards Predictions of Clinical Trial Outcomes: Combining PBPK and QSP within a Translational Diabetes PB-QSP Disease Platform

Machine-Learning Aided Multi-Scale Modelling Framework for Toxicological Endpoint Predictions in the Dog

Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis

A Generic Integrated Physiologically based Whole-body Model of the Glucose-Insulin-Glucagon Regulatory System

Considering developmental neurotoxicity in vitro data forhuman health risk assessment using physiologicallybased kinetic modeling: deltamethrin case study

Evaluation of BCRP‑Related DDIs Between Methotrexateand Cyclosporin A Using Physiologically Based PharmacokineticModelling

Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach

Augmented allometric scaling: Predicting drug clearance in farm animalswith machine learning using body weight

A generic avian physiologically-based kinetic (PBK) model and itsapplication in three bird species

Using Physiologically Based Absorption Modeling toassess the failing bioequivalence of ziprasidone capsules.

A review of OSP suite PBBM capabilities: looking ahead

Roadmap for action for advancing aggregate exposure to chemicals in the EU

Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment

Towards best use and regulatory acceptance of generic physiologicallybased kinetic (PBK) models for in vitro‑to‑in vivo extrapolation (IVIVE)in chemical risk assessment

Reproductive toxicity in birds predicted by physiologically-based kinetics and bioenergetics modelling

Considering developmental neurotoxicity in vitro data for human health risk assessment using physiologically-based kinetic modeling: deltamethrin case study

Advancing PFAS risk assessment Integrative approaches using agent-basedmodelling and physiologically-based kinetic for environmental andhealth safety

EFSA Project on the use of NAMs to explore the immunotoxicity of PFAS

Workshop Report no.40 – Chronos and Kairos: Understanding time in biology for NGRA

Report of the First ONTOX Stakeholder Network Meeting: Digging Under the Surface of ONTOX Together With the Stakeholders

A generic avian physiologically-based kinetic (PBK) model and its application in three bird species

Application of High-Throughput PBPK Modeling to Develop an IVIVE Approach for Oral Permeability

Effective exposure of chemicals in in vitro cell systems: A review of chemical distribution models

Harnessing Open-Source Solutions: Insights From the FirstOpen Systems Pharmacology (OSP) Community Conference

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference

Local depletion of large molecule drugs due to target binding in tissue interstitial space

Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule

Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy

Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment

Enhancing PB(P)K Models for the Female Reproductive Tract: A Framework for Local and Systemic Drug Kinetics

Advancing Maternal-Fetal and Lactation PBK Models for Cross-Species Risk Assessment in Toxicology

Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans

High-Throughput PBPK Framework in R using Open Systems Pharmacology Software for Anti-Tuberculosis Drug Development

Establishing quasi-steady state operations of microphysiological systems (MPS) using tissue-specific metabolic dependencies

Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS)

Translational Assessment of Drug-Induced Proximal Tubule Injury Using a Kidney Microphysiological System

Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system

A systematic review of kidney-on-a-chip-based models to study human renal (patho-)physiology